Oxford Biodynamics Plc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oxford Biodynamics Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10695
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neurodegenerative conditions. Its biomarker discovery platform is used for the detection of aberrant gene expression. The company’s products are used in the areas of breast cancer diagnostics, hepatocellular carcinoma diagnostics, nasopharyngeal carcinoma diagnostics, prostate cancer progression, melanoma diagnostics, and age related disease diagnostics. Oxford Bio is headquartered in Oxford, Oxfordshire, the UK.

Oxford Biodynamics Plc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oxford Biodynamics Plc, Medical Devices Deals, 2012 to YTD 2018 9
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
GL Capital Invests USD12.5 Million in Oxford BioDynamics 11
Partnerships 13
Oxford BioDynamics Enters into Agreement with US Biopharma Company for Biomarkers 13
Oxford BioDynamics Enters into Agreement with US Biopharma Company 14
Oxford Biodynamics Enters into Development Agreement with Two Pharmaceutical Companies 15
Equity Offering 16
Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares 16
Oxford Biodynamics Plc – Key Competitors 17
Oxford Biodynamics Plc – Key Employees 18
Oxford Biodynamics Plc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
May 22, 2018: Oxford Biodynamics: Interim Results For The Six-Month Period Ended 31 March 2018 20
Jan 30, 2018: Oxford BioDynamics Reports Revenue of £1.2m For The Year Ended 30 September 2017 21
Jun 13, 2017: Oxford Biodynamics Interim Results For The Six-Month Period Ended 31 March 2017 22
Jan 31, 2017: Oxford BioDynamics Announces Final Results for the Year Ended 30 September 2016 27
Corporate Communications 29
Sep 15, 2017: Oxford BioDynamics appoints Paul Stockdale as Chief Financial Officer and Executive Director on the Board 29
Jun 30, 2017: Oxford BioDynamics: Appointment of Paul Stockdale as Chief Financial Officer 30
Mar 09, 2017: Oxford BioDynamics announces appointment of Martin Reeves as Senior Vice President of Commercial Development 31
Feb 13, 2017: Oxford BioDynamics appoints Dr Claudio Carini as an Advisor 32
Government and Public Interest 33
Sep 18, 2018: Consortium including Oxford BioDynamics receives €4 million Horizon 2020 award 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Key Facts 2
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oxford Biodynamics Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Oxford Biodynamics Plc, Medical Devices Deals, 2012 to YTD 2018 9
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
GL Capital Invests USD12.5 Million in Oxford BioDynamics 11
Oxford BioDynamics Enters into Agreement with US Biopharma Company for Biomarkers 13
Oxford BioDynamics Enters into Agreement with US Biopharma Company 14
Oxford Biodynamics Enters into Development Agreement with Two Pharmaceutical Companies 15
Oxford BioDynamics Raises USD24.9 Million in Issue of New Ordinary Shares 16
Oxford Biodynamics Plc, Key Competitors 17
Oxford Biodynamics Plc, Key Employees 18
Oxford Biodynamics Plc, Other Locations 19

List of Figures
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oxford Biodynamics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oxford Biodynamics Plc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Oxford Biodynamics Plc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Daily Mail & General Trust plc (DMGT):企業の財務・戦略的SWOT分析
    Daily Mail & General Trust plc (DMGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Kawasaki Kisen Kaisha, Ltd.:企業の戦略・SWOT・財務分析
    Kawasaki Kisen Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kawasaki Kisen Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Rum Group for Transportation & Tourism Investment:企業の戦略・SWOT・財務情報
    Rum Group for Transportation & Tourism Investment - Strategy, SWOT and Corporate Finance Report Summary Rum Group for Transportation & Tourism Investment - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • Oki Electric Industry Co., Ltd.:企業の戦略・SWOT・財務情報
    Oki Electric Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Oki Electric Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Haemonetics Corp (HAE):企業の製品パイプライン分析2018
    Summary Haemonetics Corp (Haemonetics) is a healthcare company that offers blood management technologies and software solutions. Its portfolio includes integrated devices, information management software, and consulting services for improving clinical outcomes. It also offers a comprehensive suite o …
  • Black Knight Inc (BKI):企業の財務・戦略的SWOT分析
    Black Knight Inc (BKI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Hwa Tai Industries Berhad:企業の戦略・SWOT・財務分析
    Hwa Tai Industries Berhad - Strategy, SWOT and Corporate Finance Report Summary Hwa Tai Industries Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Crescendo Bioscience Inc-医療機器分野:企業M&A・提携分析
    Summary Crescendo Bioscience Inc (Crescendo), a subsidiary of Myriad Genetics Inc is a molecular diagnostics company that concentrates on rheumatology. The company develops quantitative, objective, and biology based tests for rheumatologists. Its vectra DA is an advanced blood test for rheumatoid ar …
  • Pivotal Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pivotal Therapeutics Inc (Pivotal Therapeutics) is a pharmaceutical company that develops and markets Omega-3 based therapies and therapeutic products for cardiovascular disorders. The company offers products such as VASCAZEN, a medical food formulated for the dietary management of an Omega- …
  • Millennium & Copthorne Hotels Plc:戦略・SWOT・企業財務分析
    Millennium & Copthorne Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary Millennium & Copthorne Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Mitsubishi Ufj Financial Group Inc
    Mitsubishi Ufj Financial Group Inc - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Ufj Financial Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • DCP Midstream LP (DCP):企業の財務・戦略的SWOT分析
    DCP Midstream LP (DCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Japan Pulp and Paper Co Ltd:戦略・SWOT・企業財務分析
    Japan Pulp and Paper Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Pulp and Paper Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Toshiba Corporation:企業の戦略・SWOT・財務情報
    Toshiba Corporation - Strategy, SWOT and Corporate Finance Report Summary Toshiba Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Pegasystems Inc (PEGA):企業の財務・戦略的SWOT分析
    Pegasystems Inc (PEGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • ChemAxon Kft:医療機器:M&Aディール及び事業提携情報
    Summary ChemAxon Kft (ChemAxon) is a provider of software platforms. The company provides chemistry and biology software solutions and consultancy services that help in optimizing the value of chemistry information in life sciences and research and development. Its product portfolio consists of desk …
  • Vodafone Group Plc (VOD):企業の財務・戦略的SWOT分析
    Vodafone Group Plc (VOD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Louisville Gas and Electric Co:電力:M&Aディール及び事業提携情報
    Summary Louisville Gas and Electric Company (LG&E) a subsidiary of LG&E and KU Energy LLC is an electric and natural gas utility. The utility offers gas storage and distribution services to residential and business customers. It has a total regulated generation capacity of three thousand megawatts. …
  • bluebird bio Inc (BLUE):企業の財務・戦略的SWOT分析
    bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Clementia Pharmaceuticals Inc (CMTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Clementia Pharmaceuticals Inc (Clementia) is a clinical stage biopharmaceutical company that focuses on the development of treatments for rare bone disorders and other diseases. Its lead product candidate Palovarotene is used for the treatment of fibrodysplasia ossificans progressiva (FOP), …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆